Holen Sie sich die Stockscreener-App
112.05
2.52%
2.75
Vorhandelsmarkt:
110.84
-1.21
-1.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$109.30
Offen:
$110.59
24-Stunden-Volumen:
7.00M
Relative Volume:
0.76
Marktkapitalisierung:
$137.40B
Einnahmen:
$28.73B
Nettoeinkommen (Verlust:
$5.97B
KGV:
23.59
EPS:
4.75
Netto-Cashflow:
$9.84B
1W Leistung:
+1.44%
1M Leistung:
+7.93%
6M Leistung:
+21.29%
1J Leistung:
+74.15%
1-Tages-Spanne:
$108.90
$112.09
1-Wochen-Bereich:
$108.90
$113.52
52-Wochen-Spanne:
$62.69
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Vergleichen Sie GILD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
112.05 | 137.40B | 28.73B | 5.97B | 9.84B | 4.75 |
|
LLY
Lilly Eli Co
|
812.03 | 687.38B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
156.66 | 369.72B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
192.42 | 331.15B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVO
Novo Nordisk Adr
|
81.05 | 322.81B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
120.77 | 232.65B | 53.22B | 12.86B | 14.85B | 6.39 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance
Gilead hit with FDA clinical hold for batch of HIV trials - Pharmaceutical Technology
Gilead Sciences Reports Promising CAR-T Therapy Results for Glioblastoma Treatment - geneonline.com
Gilead’s Trodelvy wins Korean coverage for breast cancer -- too late for some and still off-limits up front - koreabiomed.com
Levi & Korsinsky Investigates Possible Securities Fraud by Gilead Sciences, Inc. (GILD) - ACCESS Newswire
Gilead Sciences' Lenacapavir Provides 'Solid' Switching Opportunities for Current PrEP Users, RBC Says - marketscreener.com
Ex-Dividend Reminder: Gilead Sciences, CONMED and Thermo Fisher Scientific - Nasdaq
Gilead pauses trials of HIV combination therapy - statnews.com
Citi sees Gilead clinical holds as only ‘minor setback’ - Yahoo Finance
Gilead weekly oral hold should not affect lenacapavir PDUFA, says RBC Capital - Yahoo Finance
FDA placed clinical hold on Gilead HIV treatment trials of GS-1720 - Yahoo Finance
Gilead Sciences price target raised to $95 from $92 at RBC Capital - Investing.com
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down - Yahoo Finance
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views? - Nasdaq
Pharmalittle: We’re reading about Trump and drug prices, Gilead trial delays, and more - statnews.com
Gilead Sciences (GILD) Sees Price Target Boost from RBC Capital | GILD Stock News - GuruFocus
Gilead (GILD) Faces Setback with FDA Hold on HIV Treatment Trials | GILD Stock News - GuruFocus
Gilead’s HIV combo trials halted by FDA amid safety concerns - The Pharma Letter
In Brief: Gilead HIV Trials On Hold Over Safety Signal - insights.citeline.com
Five things for pharma marketers to know: Wednesday, June 11, 2025 - Medical Marketing and Media
USFDA places clinical hold Gilead Sciences trials testing HIV pill combination - Medical Dialogues
Why Gilead Scinces Stock Tumbled on Tuesday - The Globe and Mail
Why Gilead Sciences Stock Tumbled on Tuesday - The Motley Fool
FDA slaps holds on five of Gilead's HIV studies - FirstWord Pharma
Gilead Sciences (GILD) Stock Dips 1.59%, Pausing an Impressive Yearly Rally - Daily Chhattisgarh News
Gilead at Goldman Sachs Healthcare Conference: Strategic Growth Insights - Investing.com Australia
Gilead at Goldman Sachs Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com UK
US FDA pauses Gilead trials testing experimental HIV pill combination - Reuters
Transcript : Gilead Sciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11 - marketscreener.com
Gilead Sciences (GILD) Faces FDA Hold on HIV Drug Trials - GuruFocus
Gilead (GILD) Faces Setback with FDA Hold on Drug Trials | GILD Stock News - GuruFocus
US FDA places clinical hold on Gilead trials testing HIV pill combination - WSAU
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision - BioSpace
Gilead Says FDA Puts Clinical Hold on HIV Combination Trials - marketscreener.com
Gilead faces clinical hold on trials of two HIV candidates - Seeking Alpha
Gilead (GILD) Faces Clinical Hold Due to Safety Concerns in HIV Trial | GILD Stock News - GuruFocus
FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall - Fierce Biotech
Gilead (GILD) Shares Dip Amid FDA Hold on HIV Trials | GILD Stoc - GuruFocus
RBC Capital maintains Gilead Sciences stock rating, sees access hurdles - Investing.com
Gilead (GILD) Faces Clinical Hold on HIV Treatment Study | GILD Stock News - GuruFocus
GILD Faces Setback with FDA Clinical Hold on HIV Treatment Trials | GILD Stock News - GuruFocus
Gilead shares fall after FDA places clinical hold on HIV treatment trials - Proactive financial news
Gilead Sciences shares hit after HIV studies placed on hold by FDA - StreetInsider
US FDA places clinical hold on Gilead trials testing HIV pill combination By Reuters - Investing.com
FDA Pauses Trials of Gilead HIV Combination After Safety Signal - Bloomberg.com
US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination - Yahoo
US FDA Places Clinical Hold on Gilead Trials Testing HIV Pill Combination - US News Money
Gilead Sciences (GILD) Says FDA Placed Cilnical Hold On Hiv Treatment Trials - StreetInsider
Should You Be Impressed By Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE? - simplywall.st
'We are in a good spot': Gilead's new chief medical officer is committed to pipeline diversification - Fierce Biotech
2 Stocks, 100%+ Combined Gains - Investing.com
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):